Company profile: 2seventy bio
1.1 - Company Overview
Company description
- Provider of immuno-oncology cell therapies, discovering and developing cancer treatments, including ABECMA (idecabtagene vicleucel), a CAR T cell therapy for multiple myeloma developed in collaboration with Bristol Myers Squibb; leveraging expertise in cancer cell biology, genetics, and the immune response to advance its pipeline.
Products and services
- ABECMA (idecabtagene vicleucel): An immuno-oncology CAR T cell therapy co-developed with Bristol Myers Squibb for treating multiple myeloma, delivering cell therapy intervention for patients with this cancer
- Cancer Therapy Development: Cell-therapy–focused development that combines deep knowledge of cancer cell biology and genetics with understanding of the immune response to cancer to advance its pipeline of therapies
- Cancer Therapy Discovery: Genetics-informed discovery that integrates deep knowledge of cancer cell biology with immune response understanding to cancer, identifying and creating immuno-oncology therapies to expand its pipeline
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to 2seventy bio
Cell Pathways
HQ: United States
Website
- Description: Provider of small molecule-based drugs for cancer treatment leveraging an apoptosis technology platform, which can be used with other chemotherapy drugs, and of kits and methods for detection and quantification, including PCR ED ELISA kits for DIG-labeled PCR products, Endothelin-1 ELISA kits for multiple species, and combined PCR-ELISA nucleic acid detection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cell Pathways company profile →
Theraclion
HQ: France
Website
- Description: Provider of high-intensity focused ultrasound (HIFU) echotherapy medical equipment, combining HIFU with standard ultrasound for non-invasive treatment and target localization. Solutions include SONOVEIN for varicose veins; ECHOPULSE for thyroid nodules and breast fibroadenoma; CURE-OP for combinational cancer therapy integrating ultrasound with radiotherapy; and EPack single-use disposables for cooling and coupling.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theraclion company profile →
Xcell Biosciences
HQ: United States
Website
- Description: Provider of a next-generation development and manufacturing platform for enhanced cell therapy performance, offering AVATAR Foundry, an automated closed system for autologous cell therapy production (in beta); AVATAR System, an incubator that fine-tunes oxygen and pressure to mimic in vivo; AVATAR AI, software using machine learning for drug behavior prediction and potency assay development; and AVATAR AD, a four-instrument system for assay development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xcell Biosciences company profile →
Progenics Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics for cancer and related conditions, developing PSMA-targeted radioligand therapies (PNT2002, LNTH-1095), diagnostic imaging agents (LNTH-1404), and antibodies (PSMA-TAC), plus a somatostatin receptor-targeted radioligand therapy (PNT2003) for neuroendocrine tumors, alongside pipeline candidates such as PSMA ADC and LNTH-1558 in various clinical and preclinical stages.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Progenics Pharmaceuticals company profile →
LungLife AI
HQ: United States
Website
- Description: Provider of molecular diagnostics for early cancer detection and treatment, offering the LungLB® Test, a blood-based diagnostic that provides additional information to clinicians evaluating indeterminate lung nodules, potentially reducing unnecessary invasive procedures and delays in treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LungLife AI company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for 2seventy bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to 2seventy bio
2.2 - Growth funds investing in similar companies to 2seventy bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for 2seventy bio
4.2 - Public trading comparable groups for 2seventy bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →